Out-of-specification results were found for atomoxetine content and non-uniform capsule mass in batches manufactured from the same bulk batches; risk assessment indicates possible reduced therapeutic efficacy. Potential effects: possible treatment failure and worsening of disease symptoms.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
Important Information
Do not use Atofab capsules from batches E01580 and FQ6874/F06874. Check the batch number on the pack; if you have these batches, return them to the pharmacy and consult a doctor if in doubt.
The Chief Pharmaceutical Inspector suspended the distribution of Atofab 25 mg and 40 mg batches E01580 and FQ6874/F06874 throughout the country and granted the decision immediate enforceability; the p...
If you feel unwell after consuming this product, contact your doctor or call the poison control center.
FAQ
Related